TRLV
Trulieve CannabisANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Primary-source evidence supports a real operating improvement story: Trulieve reported positive Q1 net income, strong EBITDA, and strong cash generation while carrying a sizable cash balance, and federal rescheduling progress could materially improve the earnings power of a scaled U.S. cannabis operator.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cannabis rescheduling and DEA-registration benefits are not fully in the company's control and timing or scope could disappoint. [#SEC-8K-2026-05-07]
Momentum
95
Value
65
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $15.50 · Bear $8.50
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-10 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $16.26
Why
Momentum95 · Δ7d -
Value65 · Δ7d -
Sentiment56 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Sentiment
56
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 94.9 / Value 65.5 / Sentiment 55.7
Fundamentals (TTM)As of 2026-06-10
Fundamentals (TTM)
As of 2026-06-10
Market Cap
$2.21B
Beta
1.72
Shares Out
191.16M
P/E (TTM) · Derived
-19.0
P/S (TTM)
1.32
P/FCF (TTM)
11.08
Rev YoY
+1.4%
EPS YoY
+63.0%
Gross Margin
+60.8%
Op Margin
+10.9%
Net Debt
$395.6M
Current Ratio
6.09
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology